Israel-Medical-Healthcare

[genisi]

Trial didn't measure improvement in lung function only reduced lung inflammation (neutrophil count and neutrophil elastase levels). Nothing new about that -

http://www.ncbi.nlm.nih.gov/pubmed/17050563?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Kamada also didn't say if there was a change in hospitalization or any other parameter so it's hard to know if its AAT is doing better than others, as claimed by David Tzur. I believe Kamada wants to proceed to phase III anyway. Finding a partner or raising cash will not be easy.